Headache and Migraine

 
Intranasal Zavegepant for Migraine Meets Coprimary Regulatory Endpoints in Pivotal Phase 3 Trial
December 09, 2021

Intranasal CGRP inhibitor zavegepant met coprimary regulatory endpoints in pivotal phase 3 trial in adults with migraine; FDA submission planned for Q1 2022.

FDA Approves Oral CGRP Inhibitor Atogepant for Prevention of Episodic Migraine
October 01, 2021

The daily oral CGRP inhibitor is the only agent in the class developed specifically for prevention vs acute treatment of episodic migraine.

FDA Approves Intranasal DHE (Trudhesa) for Acute Migraine Treatment
September 14, 2021

The DHE nasal spray delivered pain relief at 2 hours for 66% of patients; 93% of those remained pain-free at 24 hours and 86% at 2 days post-dose.

Atogepant for Migraine Prevention Meets Primary, Secondary Endpoints
August 23, 2021

Oral CGRP inhibitor atogepant significantly reduced monthly headache days and improved daily function in adults with 4 to 14 headaches per month.

Neurology, Rheumatology, and the Gut Microbiome: Two Specialists Discuss
July 16, 2021

A neurologist and a rheumatologist sat down with Patient Care editors to talk about their focus on balance in the gut microbiome as an essential element of clinical care.

Seen in the ED: A Different Kind of Headache
April 19, 2021

A woman in her 50s who has a history of tension headache presents to the ED with a headache different from any she has had. Mild photophobia is the only finding on physical exam. Your dx?

Primary Care Physicians Face Barriers to Utilization of New Migraine Drugs
April 19, 2021

The uptake among primary care physicians of new migraine drugs has been hindered by 2 significant obstacles, a headache specialist explained to Patient Care Online.

Ditans and Gepants: Headache Specialist Discusses the Game-changing Migraine Medications
March 23, 2021

Headache specialist Peter McAllister, MD, discusses how the new migraine medications differ from existing therapies.

The Migraine Research Renaissance and Where it is Headed: A PI Interview
March 10, 2021

New and highly specific migraine drugs have significantly changed the clinical landscape for patients. We talked with Peter McAllister, MD, about where the research goes next.

Analysis of Cannabis for Pain: Is Tolerance an Issue?
February 15, 2021

Authors of 2 large cannabis-user database analyses discuss the possible reasons for observed dose increase over time by individuals using inhaled cannabis for pain relief.